Skip to main content
. 2017 Nov 28;8(69):113583–113597. doi: 10.18632/oncotarget.22745

Figure 6. Progesterone and calcitriol inhibit activity of MT1-MMP, MMP-9 and MMP-2 in cancer cells.

Figure 6

(A). HEC-1B and Ishikawa cells were treated with progesterone (PROG, 20 µmol/L), calcitriol (CAL, 100 nmol/L) or combination in the presence or absence of progesterone antagonist (RU 486) for 72 h were evaluated for activities of MT1-MMP, MMP-9 and MMP-2. Statistically significant changes in the treatment groups compared to their respective control groups are shown by asterisk (P < 0.05). (B) Knockdown of ARF6 or NEDD9 in endometrial cancer cells resulted in decreased activities of MT1-MMP, MMP-9 and MMP-2. Statistically significant changes in the ARF6 and NEDD9 knockdown groups compared to their respective control groups are shown by asterisk (P < 0.05).